Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Completed1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

completed133%
unknown133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Evaluation of the Novel Implant Disease Risk Assessment : a Retrospective Study (IDRA)

NCT04888572
completed

Gingival Crevicular Fluid Alkaline Phosphatase as Skeletal Growth Indicator

NCT04452071
withdrawnphase_1

MicroRNA and MicroRNA Inhibitors Socket Study, Pilot Clinical Trial

NCT02579187

Clinical Trials (3)

Showing 3 of 3 trials
NCT04888572

Evaluation of the Novel Implant Disease Risk Assessment : a Retrospective Study (IDRA)

Unknown
NCT04452071

Gingival Crevicular Fluid Alkaline Phosphatase as Skeletal Growth Indicator

Completed
NCT02579187Phase 1

MicroRNA and MicroRNA Inhibitors Socket Study, Pilot Clinical Trial

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3